<DOC>
	<DOCNO>NCT01284049</DOCNO>
	<brief_summary>The objective study show substitution usual lipid emulsion ( Intralipid 20 % ® ) dose 0.5 1.0 g/kg/infusion parenteral nutrition ( n-6 : n-3 ratio = 7:1 ) equivalent dose 0.5 1 g/kg/infusion another lipid emulsion , OMEGAVEN 10 % ® rich omega-3 ( n-3 ) ( n-6 : n-3 ratio = 1:7 ) induces regression PNALD due anti-inflammatory anti-fibrotic effect n-3 EFA . Regression liver disease define normalization five liver function test ( LFT ) : conjugate bilirubin , gamma GT , alkaline phosphatase , AST ALT transaminase .</brief_summary>
	<brief_title>Evaluation OMEGAVEN 10 % ® ( n-3 EFA Lipid Emulsion ) Home Parenteral Nutrition-associated Liver Disease</brief_title>
	<detailed_description>Background : Parenteral nutrition-associated liver disease ( PNALD ) context home parenteral nutrition non-neoplastic chronic intestinal failure main metabolic complication HPN , reflect combined liver intestine transplantation rate 45 % adult . Prior onset severe fibrosis , main basic histological lesion cholangitis steatosis evolve parallel abnormal liver function test ( LFT ) , prevalence increase duration HPN . An n-6 polyunsaturated fatty acid lipid supplement , base soybean oil , show major independent determinant PNALD dose great 1 g/kg/infusion . Study objective : demonstrate replacement usual lipid emulsion ( Intralipid 20 % ® ) dose 0.5 1.0 g/kg/PN infusion ( n-6 : n-3 ratio = 7 ) equivalent dose new lipid emulsion , OMEGAVEN 10 % ® , rich n-3 polyunsaturated fatty acid ( n-3 : n-6 ratio = 7 ) induces regression PNALD via anti-inflammatory anti-fibrotic effect n-3 polyunsaturated fatty acid . Material method : The treated population present severe chronic non-neoplastic intestinal failure ( rare disease ) , require HPN accredit centre . The median actuarial risk PNALD 50 % 5 year HPN adult . PNALD define inclusion 2 5 abnormal LFTs : ALT AST transaminase , conjugate bilirubin , alkaline phosphatase gamma-glutamyltranspeptidase . This multicentre prospective randomize double-blind study include patient organ failure intestinal failure especially sign decompensated cirrhosis abdominal Doppler ultrasound . It exclude unstable patient especially result recent infection ( &lt; 6 week ) . On inclusion , HPN must administer least 12 week , inclusion study , 6 week HPN devote standardization inter-centre practice . To eligible inclusion , patient must predictable duration HPN 18 week degree dependence ≥ 2 nutritional infusion per week . Other cause liver disease exclude ( viral , autoimmune , alcohol , hepatotoxic drug , biliary obstruction ) . The study duration per patient 22 week ( 6 week standardization HPN , 12 week treatment one two arm 4 week follow-up ) . HPN Intralipid 20 % ® continue unchanged HPN control arm Intralipid 20 % ® replace equivalent dose ( 0.5 1.0 g/kg/Infusion ) OMEGAVEN 10 % ® maximum dose 40 mg per infusion due formulation constraint , interventional arm . The primary endpoint normalization 5 LFT parameter 12th week treatment ( W18 ) . According publish data , probability normalization LFT le 10 % control arm 50 % treated arm . A total 32 patient must therefore recruited arm demonstrate significant difference normalization LFT 12th week treatment ( Chi-square Fisher test , p &lt; 0.05 ) two group . This population could recruit period 18 month population treat three centre participate study : Paris Ile-de-France region , Lyon Rhone-Alpes region Lille Nord-Pas de Calais region , three centre follow 50 % French adult HPN population , represent 250 patient . A monthly safety study perform clinical examination determination usual laboratory parameter . Fibrosis evaluate Fibroscan ( kilopascal ) steatosis evaluate abdominal Doppler ultrasound ( three grade ) , relevant laboratory parameter reflect lipid supplement n-3 n-6 essential fatty acid , lipoperoxidation index , explanatory factor harmful effect n-6 polyunsaturated fatty acid protective effect n-3 polyunsaturated fatty acid proinflammatory anti-inflammatory cytokine serum marker hepatic fibrosis , compare two arm begin end treatment . Expected result : This innovative prospective randomize study concern PNALD , stage cirrhosis adult , responsible patient 's death 22 % case require combine liver small intestine transplantation 45 % case . The propose therapeutic intervention , prior onset severe PNALD , base emerge rational hypothesis associate highly probable positive clinical expression .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<criteria>Age great equal 18 year . Patients HPN chronic benign intestinal failure : degree HPN dependence ≥ two cycle PN per week least one ternary infusion ( comprise lipid ) per week maximum lipid intake 40 gram per ternary infusion Expected duration HPN dependence great 18 week time inclusion . Receiving HPN least 12 week one three study centre , sufficient period allow resolution druginduced septic cholestasis cytolysis relate previous hospitalisation . Presence PNALD , define abnormality least two five liver function test perform ( conjugated bilirubin , gamma glutamyltransferase , alkaline phosphatase , AST , ALT ) . Stable patient infection six week precede inclusion . Medical examination perform inclusion . Written informed consent . Covered French national health insurance . Active cancer , regardless primary site . Uncontrolled cardiopulmonary insufficiency . Decompensated cirrhosis . Severe renal failure . Uncontrolled diabetes endocrinopathy . Hyperlipoproteinaemia hypertriglyceridaemia ( ≥ 3 mmol/L ) . Other cause liver disease ( biliary obstruction , alcohol , hepatitis B virus , hepatitis C virus , CMV , hepatotoxic drug ) . Systemic corticosteroid therapy biotherapy ( antiTNF ) . Pregnant woman nurse mother . Inclusion another study terminate less three month . Known allergy fish egg protein .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Home Parenteral Nutrition</keyword>
	<keyword>Intralipid 20 % ®</keyword>
	<keyword>OMEGAVEN 10 % ®</keyword>
	<keyword>Liver disease</keyword>
</DOC>